FDA Drug Quality Assurance Inspections: Frequency, Outcomes, and Time to Reinspection, 2008–2025

Clicks: 32
ID: 326713
2026
Free PDF
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal
Steady

Ranked #11 of 168 articles by views in Health Affairs Scholar

Most read Least read

Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 168 in total.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Sign in to mint
Abstract
Abstract Background FDA inspections are central to oversight of the pharmaceutical manufacturing base, but long-term inspection and reinspection patterns remain incompletely characterized. Methods We analyzed 25,629 FDA Drug Quality Assurance inspections conducted from October 2008 through December 2025. We described annual, regional, and outcome patterns. Linking inspections to facilities, we examined time to reinspection according to the outcome of preceding inspections. Results Annual Drug Quality Assurance inspections declined from 1,594 in 2019 to 461 in 2020 and increased to 1,218 in 2025. The United States remained the largest single region of inspection activity, but its contribution declined over time. The proportion of favorable inspection outcomes (no action indicated – NAI) decreased from 40.0% before the pandemic to 19.3% during and 23.7% after. Unfavorable outcomes (voluntary action indicated – VAI – and official action indicated – OAI) increased accordingly. The mean reinspection interval was 3.18 years after NAI, 2.96 after VAI, and 2.12 after OAI (P < .001). Median times were 4.08, 3.51, and 3.02 years, respectively. Conclusions FDA inspection activity had not returned to prepandemic levels by 2025. Unfavorable inspection outcomes were associated with earlier reinspection, consistent with risk-responsive oversight. However, the available data cannot establish whether follow-up was timely or adequate.
Reference Key
openalex_W7204450688 Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Yunxiang Sun, Jeromie Ballreich, Joy Acha, Riya Modi, Mohammad Ali Alamdar Yazdi, Maqbool Dada, Tinglong Dai, Gerard F. Anderson, Mariana P. Socal
Are you one of these authors? Claim your profile
Journal Health Affairs Scholar
Year 2026
DOI
10.1093/haschl/qxag229
URL
https://academic.oup.com/healthaffairsscholar/advance-article-pdf/doi/10.1093/haschl/qxag229/70813797/qxag229.pdf
Keywords Keywords not found

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.